Unlocking New Paths with Smart Peptides
SPIMA Therapeutics Develops Smart Peptide-Based Immunotherapies to Address Undruggable Targets
We aim at bringing to patients innovative medecines treating diseases
with challenging immunological avenues
About SPIMA Therapeutics
SPIMA Therapeutics emerges as a spin-off from the IBMM and IRMB institutes, the University of Montpellier in France, uniting experts in cutting-edge peptide chemistry and inflammation biology. The focus of our lead program is on stapled peptides targeting the Myddosome complex. This innovative approach holds immense promise for revolutionizing treatments in inflammatory and oncological diseases, offering hope where it's needed most.
SPIMA Therapeutics is part of the nexus of Landmark Bioventures
Our Technology
Locking peptides into their bioactive α-helical conformation through site-specific introduction of a chemical brace
Our technology is centered on constraining short chains of amino acids — polypeptides — in a specific folded shape known as an α-helical conformation, which confers upon them unique drug-like properties including enhanced membrane permeability and stability
This makes Stapled Peptides promising candidates for intracellular protein-protein drug targeting
Our Pipeline
Co-Founders - Executive Team
Mohamed Haitham Ayad RPh, PhD
Chief Executive Officer
Zaki Sellam
MBA, Msc
Executive Chairman
-
20+ years of experience in Biotech
-
Expert in Immuno-Oncology Drug Development - created and developed several start-ups & signed more than 40 Deals
-
20 years + of international experience in Pharma
-
Expert in early drug development, formulation/CMC and commercial-scale production
Co-Founders
Christian Jorgensen
MD, PhD
-
Head of IRMB Institute of Research on Biotherapy
-
Director of IHU IMMUN4CURE Institute for Immunotherapy
Jean Martinez
PhD, Dr Sci
-
Professor (Emeritus) at IBMM
-
Successfully discovered and developed a new drug
Florence Apparailly
PhD
-
INSERM Research Director
-
Expert in monocytes/macrophages’ biology in chronic joint inflammation and the design of targeted therapies
Muriel Amblard
PhD
-
CNRS Researcher director, Head of the department of Amino Acids, Peptides and Proteins at IBMM
-
Expert in the chemistry of Peptides
Our Ecosystem & Partners
